Literature DB >> 1539843

Context-sensitive half-time in multicompartment pharmacokinetic models for intravenous anesthetic drugs.

M A Hughes1, P S Glass, J R Jacobs.   

Abstract

Elimination half-life is the pharmacokinetic parameter used most commonly to describe duration of pharmacologic action, including that expected of intravenous anesthetic drugs administered by continuous infusion. Little consideration has been given, however, to the relevance of elimination half-life in describing plasma (central compartment) drug concentrations in the context of relevant infusion durations. Therefore, simulations were performed with multicompartment pharmacokinetic models for six intravenous anesthetic drugs. These models had elimination half-lives ranging from 111 to 577 min. The input in each simulation was an infusion regimen designed to maintain a constant plasma drug concentration for durations ranging from 1 min to 8 h and until steady state. The time required for the plasma drug concentration to decline by 50% after terminating each infusion in each of the models was determined and was designated the "context-sensitive half-time," where "context" refers to infusion duration. The context-sensitive half-times were markedly different from their respective elimination half-lives and ranged from 1 to 306 min. The half-times were explained by posing each pharmacokinetic model in the form of a hydraulic model. These simulations demonstrate that elimination half-life is of no value in characterizing disposition of intravenous anesthetic drugs during dosing periods relevant to anesthesia. We propose that context-sensitive half-times are a useful descriptor of postinfusion central compartment kinetics.

Mesh:

Substances:

Year:  1992        PMID: 1539843     DOI: 10.1097/00000542-199203000-00003

Source DB:  PubMed          Journal:  Anesthesiology        ISSN: 0003-3022            Impact factor:   7.892


  97 in total

1.  All half-lives are wrong, but some half-lives are useful.

Authors:  J G Wright; A V Boddy
Journal:  Clin Pharmacokinet       Date:  2001       Impact factor: 6.447

Review 2.  Context-sensitive half-times: what are they and how valuable are they in anaesthesiology?

Authors:  James M Bailey
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

3.  Esmolol--just another beta blocker?

Authors:  R I Hall
Journal:  Can J Anaesth       Date:  1992-10       Impact factor: 5.063

Review 4.  [Modern concepts in pharmacokinetics of intravenous anesthetics].

Authors:  T Heidegger; C F Minto; T W Schnider
Journal:  Anaesthesist       Date:  2004-01       Impact factor: 1.041

5.  Pharmacokinetic considerations for moderate and deep sedation.

Authors:  Daniel E Becker
Journal:  Anesth Prog       Date:  2011

Review 6.  Pharmacokinetic optimisation of opioid treatment in acute pain therapy.

Authors:  R N Upton; T J Semple; P E Macintyre
Journal:  Clin Pharmacokinet       Date:  1997-09       Impact factor: 6.447

Review 7.  Pharmacokinetic-pharmacodynamic modelling in anaesthesia.

Authors:  Pedro L Gambús; Iñaki F Trocóniz
Journal:  Br J Clin Pharmacol       Date:  2015-01       Impact factor: 4.335

8.  Withdrawal following sufentanil/propofol and sufentanil/midazolam. Sedation in surgical ICU patients: correlation with central nervous parameters and endogenous opioids.

Authors:  Maria Korak-Leiter; Rudolf Likar; Michael Oher; Ernst Trampitsch; Gerda Ziervogel; Joseph V Levy; Enno C Freye
Journal:  Intensive Care Med       Date:  2005-02-16       Impact factor: 17.440

9.  Functional half-life is a meaningful descriptor of steady-state pharmacokinetics of an extended-release formulation of a rapidly cleared drug : as shown by once-daily divalproex-ER.

Authors:  Sandeep Dutta; Ronald C Reed
Journal:  Clin Drug Investig       Date:  2006       Impact factor: 2.859

10.  Sevoflurane/propofol coadministration provides better recovery than sevoflurane in combined general/epidural anesthesia: a randomized clinical trial.

Authors:  Chao Liang; Ming Ding; Fang Du; Jing Cang; Zhanggang Xue
Journal:  J Anesth       Date:  2014-02-21       Impact factor: 2.078

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.